This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

G1 Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

G1 Therapeutics hat ein Gesamteigenkapital von $24.6M und eine Gesamtverschuldung von $44.3M, was einen Verschuldungsgrad von 180.2% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $98.7M bzw. $74.1M.

Wichtige Informationen

180.2%

Verhältnis von Schulden zu Eigenkapital

US$44.32m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$60.73m
Eigenkapital	US$24.59m
Gesamtverbindlichkeiten	US$74.10m
Gesamtvermögen	US$98.69m

Jüngste Berichte zur Finanzlage

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06

Recent updates

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Jul 26

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Jun 24

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: GTHXDie kurzfristigen Aktiva des Unternehmens ($92.9M) übersteigen seine kurzfristigen Passiva ($37.5M).

Langfristige Verbindlichkeiten: GTHXDie kurzfristigen Vermögenswerte des Unternehmens ($92.9M) übersteigen seine langfristigen Verbindlichkeiten ($36.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: GTHX über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: GTHXDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 180.2% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: GTHX auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: Unzureichende Daten, um festzustellen, ob GTHX über genügend Cash Runway verfügt, wenn sein freier Cashflow auf der Grundlage historischer Raten weiter wächst oder schrumpft.

This company has been acquired

G1 Therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Recent updates

G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Composite Index

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to US$0.39 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pharmacosmos Therapeutics Inc. entered into a definitive merger agreement to acquire G1 Therapeutics, Inc. (NasdaqGS:GTHX) for approximately $390 million.

New major risk - Share price stability

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

G1 Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Price target decreased by 10.0% to US$7.50

G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting

CEO, President & Director recently sold US$178k worth of stock

Consensus estimates of losses per share improve by 18%

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

G1 Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

G1 Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Forecast breakeven date pushed back to 2026

Full year 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024

Consensus estimates of losses per share improve by 22%

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

G1 Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chief Medical Officer notifies of intention to sell stock

Price target decreased by 12% to US$8.33

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC

CEO, President & Director recently sold US$108k worth of stock

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023

New minor risk - Share price stability

G1 Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023

Consensus EPS estimates upgraded to US$0.96 loss

Price target decreased by 21% to US$8.80

New minor risk - Market cap size

New minor risk - Profitability

No longer forecast to breakeven

Consensus estimates of losses per share improve by 29%

G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics Announces Appointment of Monica Thomas as Chief Compliance Officer

Forecast to breakeven in 2025

G1 Therapeutics, Inc. Presents New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate

Consensus revenue estimates increase by 26%

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2023

Consensus EPS estimates upgraded to US$2.01 loss, revenue downgraded

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates upgraded to US$2.19 loss, revenue downgraded

G1 Therapeutics, Inc. Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with Folfoxiri + Bevacizumab for Metastatic Colorectal Cancer (CRC) (Preserve 1)

Price target decreased by 45% to US$16.40

CEO, President & Director recently sold US$219k worth of stock

G1 Therapeutics, Inc. Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

CEO, President & Director notifies of intention to sell stock

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (Pfs) Data Expected in Mid-2023

G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer

G1 Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.05 million.

Price target decreased to US$32.86

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (Adc)